FDA Clears Voruciclib for Phase 1 Trial as Potential Treatment for Certain B-cell Malignancies
News
The U.S. Food and Drug Administration (FDA) has cleared the way for MEI Pharma to launch a Phase 1 study of voruciclib, its oral CDK9 inhibitor, to treat people with ... Read more